Research Continues for Best Immunotherapy Order in Advanced RCC
Even with the increase of immunotherapy utilization to treat patients with advanced renal cell carcinoma, more research is needed to determine in which order to administer it as later lines of therapy.
In Kidney Cancer Treatment, ‘Personalized Biomarkers Work’
Therapies that target specific characteristics on kidney cancer cells are showing promise in the space, an expert explained.
‘It’s a Time of Hope’ for Kidney Cancer
With new treatments being explored, it’s an exciting time for patients with kidney cancer, an expert explained.
How Cancer Teams Leverage Biology in Guiding First-Line Therapy for Clear Cell RCC
An expert explained what aspects of a patient’s disease cancer care teams use to determine the best treatment options for patients with clear cell renal cell carcinoma.
BAP1-Mutated RCC Responds to Treatment with Lynparza
Patients with BAP1-mutated renal cell carcinoma who were treated with Lynparza obtained responses with favorable side effect profiles.
New Drugs Being Explored in Kidney Cancer
An expert gives an overview of up-and-coming treatments for patients with kidney cancer.
Drug Duo Continues to Show Promise in Advanced Kidney Cancer
Long-term follow-up data showed that Lenvima plus Keytruda continued to show benefit in patients with metastatic kidney cancer.
Upfront Immunotherapy Delays Surgery, Improves Metastatic Kidney Cancer Control
Immunotherapy combinations tended to improve outcomes for patients with metastatic kidney cancer who go on to receive surgery.
Radiation Effective, Does Not Worsen Quality of Life in Kidney Cancer
Radiation is an emerging treatment modality in kidney cancer. Research shows that it is effective and helps patients maintain a good quality of life.
Keytruda Prolongs Time Without Cancer Signs, Symptoms in Clear Cell RCC
Keytruda after nephrectomy improved disease-free survival rates in patients with clear cell renal cell carcinoma regardless of disease risk or stage.
Lenvima, Keytruda Elicits Greater Responses Than Sutent in Advanced RCC
Responses to treatment with Lenvima plus Keytruda for advanced renal cell carcinoma were present regardless of PD-L1 status.
Insurance Type May Indicate Survival Outcomes in Metastatic RCC
Patients with Medicaid or no insurance may have worse survival outcomes compared with Medicare or private insurance in those with metastatic renal cell carcinoma.
Immigrant Cancer Survivors Face Higher Rates of Uninsurance, Financial Hardship, Food Insecurity
Immigrant and foreign-born cancer survivors experience several disparities that suggest barriers to care and “may portent worse health outcomes in cancer survivorship,” according to researchers.
Lacking Emotional Support May Impact Quality of Life in Older Patients With GI Cancers
Patients 60 years and older with gastrointestinal cancers who reported inadequate emotional support were more likely to have poorer physical and mental quality of life, although no effect was observed in overall survival.
‘Reassuring’ Findings Show That Flu Shot Is Safe During Immunotherapy
Patients with cancer undergoing immunotherapy treatment did not have increased hospitalizations or serious side effects after getting the flu shot.
Jaktinib Further Improves Spleen Volume in Myelofibrosis
Jaktinib significantly improved spleen volume reduction rates compared with hydroxyurea in intermediate- to high-risk myelofibrosis.
‘There’s a Lot of Innovation’ in the KRAS-Mutant Lung Cancer Space
An expert discusses the ongoing SPARK trial for KRASG12-mutant non-small cell lung cancer, and what she hopes for the future of this patient population.
Educated Patient® MPN Summit Myelofibrosis Panel: May 20, 2023
Watch Dr. Rami Komrokji and Dr. John O. Mascarenhas answer questions about myelofibrosis during the CURE® Educated Patient® MPN Summit.
Chemoimmunotherapy Responses May Allow for Omission of Radiotherapy in Lymphoma
Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities.
Educated Patient® MPN Summit Novel Drugs And Combinations for MF Presentation: May 20, 2023
Watch Dr. John O. Mascarenhas, from Icahn School of Medicine, discuss novel therapies in myelofibrosis during the CURE® Educated Patient® MPN Summit.
Educated Patient® MPN Summit Risk Stratification and Management of MF Presentation: May 20, 2023
Watch Dr. Rami Komrokji, from Moffitt Cancer Center, discuss risk stratification and management of myelofibrosis during the CURE® Educated Patient® MPN Summit.
Educated Patient® MPN Summit Polycythemia Vera Panel: May 20, 2023
Watch Dr. Nikolai Podoltsev, Dr. Jerry Spivak and Amy Lane answer questions about polycythemia vera during the CURE® Educated Patient® MPN Summit.
Educated Patient® MPN Summit On The Horizon For PV Management Presentation: May 20, 2023
Watch Dr. Jerry Spivak, from Johns Hopkins University School of Medicine, discuss what is on the horizon in the management of polycythemia vera during the CURE® Educated Patient® MPN Summit.
Study Shows ‘A Lot of Hope’ for Prostate Cancer Treatment
Most patients with nonmetastatic castration-resistant prostate cancer were able to stay on their therapies long-term, research showed.
Pre- or Post-Transplant Xospata Shows Relapse-Free Survival Benefit in AML Group
Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.
Educated Patient® MPN Summit Current Management of PV Presentation: May 20, 2023
Watch Dr. Nikolai Podoltsev, from Yale School of Medicine, discuss the current management of polycythemia vera during the CURE® Educated Patient® MPN Summit.
Educated Patient® MPN Summit Essential Thrombocythemia Panel: May 20, 2023
Watch Dr. Lucia Masarova, Dr. Laura C. Michaelis and Celia Militz answer questions about essential thrombocythemia during the CURE® Educated Patient® MPN Summit.
More CAR-T Cell Therapies Will ‘Ease Out the Shortage’
CAR-T cell therapies have not always been easy to access for patients with myeloma, though that is slowly changing, an expert explained.
Educated Patient® MPN Summit Current Management and Trials on the Horizon in ET Presentation: May 20, 2023
Watch Dr. Laura C. Michaelis, from the Medical College of Wisconsin, discuss the current and future management of essential thrombocythemia during the CURE® Educated Patient® MPN Summit.
Standard Approach for Inactive, Early CLL Remains a Wait-and-Watch Strategy
Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.
2 Clarke Drive Cranbury, NJ 08512